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calculated from the date of surgery until the date of death or 
until the last known vital status. Conditional survival was 
defined as the survival conditional on surviving one year after 
surgery and was calculated in order to avoid the impact of 
adverse events in the postoperative course.  
Multivariable Cox proportional-hazards regression models 
were applied to evaluate the association of preoperative 
treatment, type of radical resection and use of adjuvant 
chemotherapy with survival, adjusting for the baseline 
characteristics age, gender, WHO score and clinical stage.  
 
Results: A total of 5173 eligible rectal cancer patients were 
identified from the national database. Preoperative 
treatment was as follows: none in 1354 (26.2%), radiotherapy 
in 797 (15.4%) and chemoradiotherapy in 3022 (58.4%) 
patients. Patients who received no preoperative therapy or 
preoperative radiotherapy and those who underwent 
abdominoperineal resection had a lower observed survival as 
compared with patients receiving preoperative 
chemoradiotherapy or treated with sphincter-sparing surgery 
respectively (Table). The patient group receiving adjuvant 
chemotherapy had a worse observed survival than the group 
receiving no adjuvant therapy. These effects were age-
dependent. Multivariable analysis demonstrated similar 
findings for the observed survival conditional on surviving the 
first year after surgery. 
 
Conclusion: In this population-based study, preoperative 
chemoradiotherapy, sphincter-sparing surgery and no 
adjuvant chemotherapy were associated with a superior 
survival in clinical stage I-III rectal cancer patients. 
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Purpose or Objective: To model acute hematologic toxicity 
(HT) and dose to pelvic osseous structures in anal cancer 
patients treated with definitive chemo-radiation (CT-RT). 
 
Material and Methods: 53 patients receiving CT-RT were 
analyzed. Pelvic bone marrow (PBM) and corresponding 
subsites were contoured: ilium (IBM), lower pelvis (LPBM) and 
lumbosacral spine (LSBM). Dose-volume histograms points and 
mean doses were collected. Logistic regression was 
performed to correlate dosimetric parameters and > G2-G3 
HT as endpoint. Normal tissue complication probability 
(NTCP) was evaluated with the Lyman-Kutcher-Burman (LKB) 
model. 
 
Results: Logistic regression showed a significant correlation 
between LSBM mean dose and >G2 neutropenia (β 
coefficient:0.109;p=0.037;95%CI:0.006-0.212) and >G3 
leukopenia (β coefficient:0.122; p=0.030;95% CI:0.012-0.233) 
(Table 1). According to NTCP modeling, the predicted HT 
probability had the following parameters: TD50:32.6 Gy, 
γ50:0.89, m:0.449 (>G2 neutropenia) and TD50:37.5 Gy, 
γ50:1.15, m:0.347 (>G3 leukopenia) (Figure 1). For node 
positive patients TD50:30.6 Gy, γ50:2.20, m:0.181 (>G2 
neutropenia) and TD50:35.2 Gy, γ50:2.27, m:0.176 (>G3 
leukopenia) were found (Figure 1) 
 
 
.  
Node positive patients had significantly higher PBM-V15 
(Mean:81.1%vs86.7%;p=0.04), -V20 
(Mean:72.7%vs79.9%;p=0.01) and V30 
(Mean:50.2%vsMean:57.3%;p=0.03).Patients with a mean 
LSBM dose >32 Gy had a 1.31 (95%CI:0.75-2.35) and 1.81 
(95%CI:0.81-4.0) relative risk to develop >G2 neutropenia and 
>G3 leukopenia. For node positive patients those risks were 
1.67 (95%CI:0.76-3.64) and 2.67 (95%CI:0.71-10).To have a 
<5%, <10%,<20% risk to develop >G2 neutropenia and >G3 
leukopenia, LSBM mean dose should be below 6 Gy, 13 Gy and 
20 Gy and 14 Gy, 20 Gy and 26 Gy, respectively. For node 
positive patients these thresholds were below 21 Gy, 23 Gy 
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and 26 Gy (>G2 neutropenia) and 24 Gy, 27 Gy and 30 Gy 
(>G3 leukopenia). On the whole cohort, within a dose range 
between 25 and 40 Gy, this probability rises from 30.3% to 
69.1% for >G2 neutropenia and from 17.5% to 57.1% for >G3 
leukopenia. For node positive patients these ranges were 
16.5%-93.7% (>G2 neutropenia) and 6.7%-77.6% (>G3 
leukopenia). 
 
Conclusion: LKB modeling seems to suggest that LSBM mean 
dose should be kept below 32 Gy to minimize > G2-G3 HT in 
anal cancer patients treated with IMRT and concurrent 
chemotherapy. The sensitivity of LSBM and its contribution to 
the development of HT above 25 Gy seems higher in node 
positive patients. 
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Purpose or Objective: RTCT is widely used as treatment in 
LARC before surgery. A challenging aspect for tailoring 
radiation dose prescription is prediction of cases that will 
show a pathological complete response (PCR) after surgery, 
because they have better expectation in survival outcomes. 
“Radiomics” refers to the extraction and analysis of large 
amounts of advanced quantitative imaging features with high 
throughput from medical images. Up today radiomics findings 
in LARC have been limited either to small case series and CT 
or PET scan imaging. Objective of this study is to find a 
radiomics signature able to distinguish PCR patients using 
pre-treatment MR. 
Material and Methods: Histologically proven LARC patients 
were recruited retrospectively since May 2008 to December 
2014. They were staged by T2 MR, high resolution ( .7 x .7 x 3 
mm pixel spacing on x-y-z axes) perpendicular to tumor 
major axis oblique scans, before RTCT start. Finally they 
underwent to surgery with definition of pathological 
response. All patients were addressed to RTCT treatment 
with 50.4 Gy @ 1.8 Gy/fr prescription dose on 
GTV+surrounding mesorectum (PTV1) and 45 Gy @ 1.8 Gy/fr 
on lymphatic drainage (PTV2). For radiomics analysis GTV was 
delineated on pre treatment MRI by a radiologist and a 
radiation oncologist experienced in GI. Images were 
processed by using a home-made software. Before analysis 
MR images were pre-processed using a normalization 
procedure and application of Laplacian of Gaussian (LoG) 
filter on raw data. After pre-processing, GTV volumes were 
analyzed extracting 1st order features (Kurtosis, Skewness 
and Entropy). These features were extracted by scanning all 
possible values of σ in LoG filter from 0.3 to 6 (step 0.01). A 
total number of 570 x 3 features were analyzed respect to 
the PCR in order to detect the most significant ones using 
AUC and Mann-Whitney test. Tumor clinical (cT, cN) and 
geometrical features (volume, surface, volume/surface ratio) 
were finally added for building a multivariate logistic model 
and predicting PCR. Model performance was evaluated by 
ROC analysis and internal bootstrapping for detecting 
calibration error (TRIPOD Ib classification). 
 
Results: 173 patients have been enrolled in this study. 1st 
order features analysis shows as candidate-to-analysis ones 
the Skewness (σ=0.69 - SK069) and Entropy (σ=0.49 - EN049). 
Multivariate logistic model shows as significant covariates cT 
(p-val = 0.003), SK069 (p-val = 0.006) and EN049 (p-val = 
0.049). AUC of model is 0.73 and bootstrap based internal 
calibration shows prediction mean absolute error = 0.017. 
The model has been summarized in a nomogram. 
 
 
Conclusion: This is the first radiomics model able to predict 
PCR in LARC patients only using pre-treatment imaging. 
Model performance is fair but its limitation is in the 
availability of internal validation alone. External validation is 
already planned. Use of such a model could address patients 
to different treatment pathways according outcome 
expectation. 
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Purpose or Objective: Predictive and prognostic models in 
locally advanced rectal cancer have been developed in the 
last years. Starting with predictions models on pathologic 
complete response (as intermediate endpoint), afterwards 
local recurrence (LR), distant metastasis (DM) and overall 
survival (OS) at different time points (e.g. 5 or 10 years post-
treatment) finally resulting in a model for the aggregate 
outcome, disease free survival (DFS). The current work aimed 
to reproduce the prediction models for LR, DM and OS, and to 
investigate the time dependence of these models. 
 
Material and Methods: The dataset characteristics are shown 
in Table 1. This pooled dataset merged the datasets of the 
ACCORD, TME, CAO/ARO/AIO '94, Polish, FFCD, Italian 
(Sainato) and UK (Glynne-Jones) trials. As the current pooled 
dataset contains different trials, we used 20% of patients 
(stratified on the trial) as a validation dataset. In accordance 
to the methods used in previous work, we trained prediction 
models for the outcomes LR, DM and OS on this larger 
